Addressing the questions of tomorrow: Melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma

Expert Opinion on Investigational Drugs

Volumn 22, Issue 5, 2013, Pages 619-634

  Martino, Massimo ^a   Olivieri, Attilio ^b   Offidani, Massimo ^b   Vigna, Ernesto ^c   Moscato, Tiziana ^a   Fedele, Roberta ^a   Montanari, Mauro ^b   Console, Giuseppe ^a   Gentile, Massimo ^c   Messina, Giuseppe ^a   Irrera, Giuseppe ^a   Morabito, Fortunato ^c  

^a Bone Marrow Transplant Unit   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c Azienda Ospedaliera   (Italy)

Author keywords

Autologous hematopoietic progenitor cell transplantation; Conditioning regiments; High dose chemotherapy; Multiple myeloma

Indexed keywords

AMIFOSTINE; AMPHOTERICIN; ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; KERATINOCYTE GROWTH FACTOR; MELPHALAN; POLYMYXIN; THALIDOMIDE; TOBRAMYCIN;

AREA UNDER THE CURVE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CRYOTHERAPY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; HONEY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; META ANALYSIS (TOPIC); MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; ORAL MUCOSITIS; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TOTAL PARENTERAL NUTRITION; VOMITING;

ANTINEOPLASTIC AGENTS, ALKYLATING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MELPHALAN; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84876230870     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.788643     Document Type: Review

References (137)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. Cancer J Clin 2012;62:10-29
2. Durie BG, Salmon S. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54
3. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98
4. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol 2005;32:S24-30
5. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-86
6. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3
7. Laubach JP, Mitsiades CS, Mahindra A, et al. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw 2009;7:947-60
8. Jagannath S, Kyle RA, Palumbo A, et al. The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk 2010;10:28-43
9. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of Autologous Bone Marrow Transplantation and chemotherapy in Multiple Myeloma. N Engl J Med 1996;335:91-7
10. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-6
11. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83
12. Bladé J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755-9
13. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227-33
14. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929-36
15. Giralt S. Stem cell transplantation for multiple myeloma: current and future status. Hematology 2012;17(Suppl 1):S117-20
16. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139-46
17. Chanan-Kahn A, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010;28:2612-24
18. Harousseau JL, Moreau P. Autologous hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-54
19. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009;114:5436-43
20. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografter myeloma. J Clin Oncol 2010;28:2077-84
21. Mellqvist UH, Westin J, Gimsing P, et al. Improved response rate with bortezomib consolidation after high-dose melphalan: first results of a nordic myeloma study group randomized phase III trial. Blood 2009;114:530a
22. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. NEJM 2012;366:1782-91
23. Ludwig H, Durie BG McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012;119:3003-15
24. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-81
25. Moreau P, Attal M, Harousseau JL. New developments in conditioning regimens before auto-SCT in multiple myeloma. Bone Marrow Transplant 2011;46(7):911-15
26. Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012;119(9):2100-5
27. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117(18):4696-700
28. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009;84(12):1095-110
29. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011;8:479-91
30. Krishnan A. American Society Clinical Oncology Annual Meeting. Educational Book 2012. p. 502-7
31. Gertz MA, Ansell SM, Dingli D, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008;83(10):1131-8
32. Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematol Am Soc Hematol Educ Program 2012;2012:354-61
33. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before and consolidation therapy after double autologous stem cell transplantation in newly diagnosed multiple myeloma. A randomized phase 3 study. Lancet 2010;376:2075-85
34. Hahn T, Wingard J, Anderson K, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant 2003;9:4-37
35. Barosi G, Boccadoro M, Cavo M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004;89(6):717-41
36. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132(4):410-51. 23-25
37. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13(2):183-96
38. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-93
39. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349(26):2495-502
40. Harousseau JL. Hematopoietic stem cell transplantation in multiple myeloma. J Natl Compr Canc Netw 2009;7:961-70
41. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. J Clin Oncol 2007;25(17):2434-41
42. Naumann-Winter F, Greb A, Borchmann P, et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 2012;10:CD004626
43. Patriarca F, Petrucci MT, Bringhen S, et al. Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 2009;82:93-105
44. Palumbo A, Rajkumar SV. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Eur J Haematol 2010;84:379-90
45. Blade' J, Rosinol L, Cibeira MT, et al. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010;115:3655-63
46. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008;26(3):480-92
47. Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newlydiagnosed multiple myeloma. Br J Haematol 2009;145(6):681-708
48. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117(23):6063-73
49. Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012;47(7):906-23
50. Reece DE, Bredeson C, Perez WS, et al. Autologous stem cell transplantation in multiple myeloma patients 60 vs 60 years of age. Bone Marrow Transplant 2003;32(12):1135-43
51. Bergel F, Stock JA. Cytotoxic alpha amino acids and endopeptidase. Br Emp Cancer Comp Annu 1953;31:6-21
52. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol 1988;6:1768-82
53. Bayraktar UD, Bashir Q, Qazilbash M, et al. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19(3):344-56
54. Singhal S, Powles R, Treleaven J, et al. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant 1996;18:1049-55
55. Hersh MR, Ludden TM, Kuhn JG, Knight WA III. Pharmacokinetics of high dose melphalan. Invest New Drugs 1983;1:331-4
56. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995;13:1786-99
57. Lazarus HM, Herzig RH, Graham-Pole J, et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983;1:359-67
58. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007;12:738-47
59. Amifostine: BC Cancer Agency. British Columbia Cancer Agency. 2006. Available from: http://www. bccancer. bc. ca/HPI/DrugDatabase/DrugIndexPro/ amifostine. htm
60. Capelli D, Santini G, De Souza C, et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000;110(2):300-7
61. Phillips GL II, Bernstein SH, Liesveld JL, et al. A phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant 2011;17:1033-42
62. Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37(11):1031-5
63. Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2011(4):CD000978
64. Selby PJ, McElwain TJ, Nandi AC, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987;66:55-62
65. Pritchard J, McElwain TJ, Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 1982;45:86-94
66. Westerfield BT, Michalski JP, McCombs C, Light RW. Reversible melphalan-induced lung damage. Am J Med 1980;68:767-71
67. Olivieri A, Corvatta L, Montanari M, et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant 1998;21:1049-53
68. Yang J, Terebelo HR, Zonder JA. Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited. Adv Hematol 2012;2012:801495
69. Blokhin N, Larionov L, Perevodchikova N, et al. Clinical experiences with sarcolysin in neoplastic diseases. Ann NY Acad Sci 1958;68:1128-32
70. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2(8354):822-4
71. Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986;67:1298-301
72. Giralt S. 200mg/m2 melphalan-the gold standard for multiple myeloma. Nat Rev 2010;7:490-1
73. Cunningham D, Paz-Ares L, Milan S, et al. High dose Melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-63
74. Jagannath S, Vesole DH, Glenn L, et al. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992;80:1666-72
75. Moreau P, Milpied N, Mahe B, et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999;23:1003-6
76. Philips GL, Meisenberg BR, Reece DE, et al. Activity of single-agent melphalan 220 to 300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2004;10:473-83
77. Palumbo A, Bringhen S, Bruno B, et al. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010;115(10):1873-9
78. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 2008;83:614-17
79. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001;114:600-7
80. Bashir Q, Shah N, Parmar S, et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged /=70 years with multiple myeloma. Leuk Lymphoma 2012;53:118-22
81. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114:822-9
82. Raab MS, Breitkreutz I, Hundemer M, et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006;91:1555-8
83. Parikh GC, Amjad AI, Saliba RM, et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009;15:812-16
84. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51-4
85. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94:1248-53
86. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052-7
87. Lenhoff S, Hjorth M, Westin J, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006;133:389-96
88. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet 2007;370:1209-18
89. Shaw PJ, Nath CE, Nivison-Smith I, et al. Higher melphalan exposure is associated with improved overall survival for myeloma patients undergoing autologous transplant. Biol Blood Marrow Transplant 2012;18:S207
90. Barlogie B, Alexanian R, Dicke K, et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987;70:869-72
91. Adkins DR, DiPersio JF. Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose? Curr Opin Hematol 2008;15:555-60
92. Zaucha RE, Buckner DC, Barnett T, et al. Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. Int J Radiat Oncol Biol Phys 2006;64:227-34
93. Moreau P, Facon T, Leleu X, et al. Comparison of 200 mg/mq melphalan and 8 Gy total body irradiation plus 140 mg/mq melphalan as conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the intergroup11 Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-5
94. Goldschmidt H, Hegenbart U, Wallmeier M, et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol 1997;8:243-6
95. Bjorkstrand B, Svensson H, Goldschmidt H, et al. 5489 autotransplants in multiple myeloma: a registry from the EBMT Blood 1999;94(Suppl 1):714 a
96. Wong JY, Rosenthal J, Liu A, et al. Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys 2009;73:273-9
97. Schultheiss TE, Wong J, Liu A, et al. Image-guided total marrow and total lymphatic irradiation using helical tomotherapy. Int J Radiat Oncol Biol Phys 2007;67:1259-67
98. Somlo G, Spielberger R, Frankel P, et al. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res 2011;17(1):174-82
99. Galaup A, Paci A. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. Expert Opin Drug Metab Toxicol 2012
100. Lahuerta JJ, Grande C, Blade J, et al. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. Leuk Lymphoma 2002;43(1):67-74
101. Lahuerta JJ, Martinez-Lopez J, Grande C, et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 2000;109(1):138-47
102. Carreras E, Rosinol L, Terol MJ, et al. Veno occlusive disease of the liver after high dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007;13(12):1448-54
103. Lahuerta JJ, Mateos MV, Martínez-López J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 2010;95(11):1913-20
104. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15(5):523-36
105. Krivoy N, Hoffer E, Lurie Y, et al. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf 2008;3(1):60-6
106. Blanes M, de la Rubia J, Lahuerta JJ, et al. Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leuk Lymphoma 2009;50(2):216-22
107. Stadtmauer EA, Ratanatharathorn V, Yeh RF. Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation. ASH; 2012
108. BuMel Conditioning Regimen for ASCT in Newly Diagnosed Multiple Myeloma Patients + Lenalidomide Maintenance After ASCT (BuMelMCRN001) ClinicalTrials. gov identifier: NCT01702831
109. Korycka-Wolowiec A, Robak T. Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opin Drug Metab Toxicol 2012;8(11):1455-68
110. Leoni LM, Hartley JA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol 2011;48(Suppl 1):S12-23
111. Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011;118(12):3419-25
112. Ponisch W, Bourgeois M, Moll B, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 2013;139(3):499-508
113. Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;160(3):321-30
114. Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma. ClinicalTrials. gov identifier: NCT00916058
115. Mark TM, Reid W, Niesvizky R, et al. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplant in multiple myeloma. Biol Blood Marrow Transplant 2013; pii: S1083-8791(13)00098-0. doi: 10. 1016/j. bbmt. 2013. 02. 013
116. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59(11):2615-22
117. Mitsiades N, Mitsiades C, Richardson P, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80
118. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359(9):906-17
119. Yarde DN, Oliveira V, Mathews L, et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009;69:9367-75
120. Nishihori T, Alekshun TJ, Shain K, et al. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol 2012;157(5):553-63
121. Roussel M, Moreau P, Huynh A, et al. Bortezomib ad high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010;115:32-7
122. Thompson PA, Prince HM, Seymour JF, et al. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pretreated multiple myeloma. Bone Marrow Transplant 2011;46:764-5
123. Lee SR, Kim SJ, Park Y. Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. Korean J Hematol 2010;45(3):183-7
124. Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose and schedule finding study. Clin Cancer Res 2010;16:5079-86
125. Wong Doo N, Thompson P, Prince H, et al. Bortezomib with high dose melphalan conditioning for autologous transplantation is safe and effective in patients with heavily pre-treated and high risk multiple myeloma. Leuk Lymphoma 2012; Epub ahead of print
126. Huang W, Li J, Li H, et al. High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy. Leuk Lymphoma 2012;53(12):2507-10
127. Kim JS, Min CK, Yoon SS, et al. A phase 1/2, open-label, prospective, multicenter study to evaluate the efficacy and safety of the lower dose of bortezomib plus busulfan and melphalan as a conditioning regimen in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation: result of phase 1 trial. Blood (ASH Annual Meeting Abstracts) 2012. 120: 1937
128. McCormack PL. Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma. Drugs 2012;72(15):2023-32
129. Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation ClinicalTrials. gov identifier: NCT01690143
130. Berenson JR, Boccia R, Siegel D, et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 2006;135:174-83
131. Qazilbash MH, Saliba RM, Nieto Y, et al. Arsenic trioxide with ascorbic acid and high dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 2008;14:1401-7
132. Sharma M, Khan H, Thall PF, et al. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 2012;118(9):2507-15
133. Giralt S, Bensinger W, Goodman M, et al. 166Ho DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 2003;102(7):2684-91
134. Christoforidou AV, Saliba RM, Williams P, et al. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166) Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 2007;13(5):543-9
135. Dispenzieri A, Wiseman GA, Lacy MQ, et al. A phase II study of (153) Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol 2010;85:409-13
136. Dispenzieri A, Gertz MA, Lacy MQ, et al. A phase I trial of zevalin radioimmunotherapy with high-dose melphalan (HDM) and autologous stem cell transplant (ASCT) for multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2011;118:3095
137. Paíno T, Ocio EM, Paiva B, et al. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica 2012;97(7):1110-14